NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

sukus. I've quoted them several times over the years.

They have several sets of figures which they seem to shuffle around at their convenience, including an interim analysis set (which got them approval), a 'final analysis' set (not as good as the interim figures), an ITT set and a PP (per protocol) set!

But the ones they used to generally quote were:-

1yr: Optune 73%, control 65%
2yr: Optune 43%, control 31%
3yr: Optune 26%, control 16%
4yr: Optune 20%, control 8%
5yr: Optune 13%, control 5%.

Bear in mind they measured from randomization, and not from surgery, so this actually depresses their figures somewhat in the early years, especially 1yr, but also 2yr somewhat.

I actually did a 'reblend' exercise on their arm by arm figures, a year or two back, so as to be able to make a comparison with our blended yearly milestones, but I've lost the post!

Suffice to say, our survival figures match theirs up to 2yrs, as does median OS, but anything beyond 2yrs, DCVax figures pull away to clear superiority, and the further you go, the greater the superiority.

Another thing that makes their figures difficult to interpret is that 32.66% of all the patients in the trial had unknown meth status or an invalid test result.

Why should this be? There is no acceptable explanation available.
Testing was widely available by this time.

And another thing they did is they waited a mean 3.9 months before randomizing. And at least a couple of patients weren't randomized until 16 months from diagnosis!

Having said all of that, I do think it probably works a bit.